Ictastan (Emtricitabine, Tenofovir Disoproxil Succinate)

Emtricitabine is a nucleoside reverse transcriptase inhibitor. Inside cells it is converted to its active triphosphate form, which competes with natural nucleotides and causes premature termination of the viral DNA chain during reverse transcription, thereby blocking HIV replication.

The specific dose of Ictastan is determined by the prescribing clinician based on the patient’s clinical condition, weight, renal function and other medications. Patients should follow the exact regimen provided by their healthcare professional.

Safety in pregnancy and lactation should be evaluated by a specialist. The benefits of controlling HIV infection often outweigh potential risks, but the prescriber must assess each case individually and discuss possible effects with the patient.

To place an order, submit an enquiry on the Ictastan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ictastan combines two reverse transcriptase inhibitors, offering a dual mechanism that can simplify regimens compared with single‑agent NRTIs. It is often used as a backbone in first‑line therapy, providing comparable efficacy to other fixed‑dose combinations while maintaining a well‑characterised safety profile.

Ictastan tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Do not store in areas of high humidity or extreme temperature to preserve potency.

Ictastan is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include lactic acidosis, severe hepatotoxicity, renal impairment, hypersensitivity reactions and rare severe skin disorders such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained fatigue, abdominal pain, jaundice, swelling or rash.

Ictastan is contraindicated in patients with known hypersensitivity to emtricitabine, tenofovir or any of the tablet’s excipients. It should also be avoided in individuals with severe renal impairment unless dose adjustments are made under specialist supervision.